Bone Marrow Transplantation correct treatment of these patients is not easy at present. We do not know of any prognostic factors separating e19a2 CML patients into mild, average and high risk groups, but we must remember that some of these patients can go through an acceleration and transformation. In our opinion, the only possibility at present is to monitor the development of disease in these patients very carefully. As soon as the first signs of previous treatment refractoriness and acceleration are noticed, allogeneic transplantation should be indicated in cases with an accessible marrow donor. A severe course of the disease in our patient was documented by refractoriness to the chemotherapy treatment and by a development of an accelerated phase. To our knowledge, our patient is the first case of a micro bcr CML patient to be treated by bone marrow transplantation. 
Factor V Leiden mutation as a predisposing factor for veno-occlusive disease following BMT
In a recent issue of this journal, Duggan et al 1 retrospectively evaluated the importance of factor V Leiden (1691 G-A) and the prothrombin gene 20210 G-A mutations as a predisposing factor for veno-occlusive disease (VOD) following BMT. In their study, 15 of the 22 patients who developed VOD and 51 patients without VOD following BMT were evaluated. The authors concluded that the prothrombin gene 20210 G-A but not factor V Leiden mutation may increase the risk of VOD in BMT patients but also that prospective confirmation with larger studies is needed. We would like to share our experience which is in contrast with the conclusion of this study.
In December 1997, we initiated a prospective study in children, looking at the association of inherited abnormalities known to predispose to thrombosis and VOD following BMT. VOD was diagnosed on the basis of clinical criteria, as previously described, 2 similar to Duggan et al's study. Severity of VOD was scored as mild, moderate or severe as previously defined. 2 The laboratory evaluation of inherited hypercoagulable abnormalities included functional anticoagulant assays for protein C, protein S, antithrombin III (ATIII), factor VIII and genetic analysis of the factor V Leiden and prothrombin 20210 G-A mutation before conditioning therapy. Genetic analyses were performed as previously described. 3, 4 In this ongoing prospective study, 10 consecutive children who received allogeneic BMT were included. The underlying diseases were as follows: AML (n = 5), juvenile myelomonocytic leukemia (n = 1), ␤-thalassemia major (n = 2), SAA (n = 1), Fanconi's anemia (FA; n = 1). Conditioning therapy was with BU 640 mg/m 2 and CY 200 mg/kg for leukemia, BU 480 mg/m 2 and CY 200 mg/kg for thalassemia, ATG (horse, Pasteur-Merieux, Lyon, France) 30 mg/kg and CY 200 mg/kg for SAA, BU 6 mg/kg and CY 40 mg/kg for FA.
There were four cases of VOD: one patient with thalassemia had mild and three patients (two AML, one thalassemia) had moderate VOD. Laboratory evaluation of inherited hypercoagulable abnormalities indicated that three of the four had factor V Leiden heterozygosity. None of these patients had prothrombin gene 20210 G-A mutation. Protein C, protein S, ATIII, and factor VIII levels were in the normal range. Our previous population study 3 had revealed that factor V Leiden heterozygosity was 9.8% with an allelic frequency of 4.9 which is one of the highest in the Western population. Prothrombin gene 20210 G-A heterozygosity was also found to be 2.7% in the Turkish population.
The clinical syndrome of VOD of the liver is one of the major regimen-related toxicities that can occur after highdose cytoreductive therapy. Recent morphologic data have indicated that the injury of hepatic venular or sinusoidal endothelium is believed to be one of the earliest events in the pathogenesis of VOD. When endothelial cells are perturbed, a hypercoagulable state is formed locally and hepatic venular occlusion occurs. Several investigators have reported an acquired hypercoagulable state with low levels of the naturally occurring anticoagulants, protein C and ATIII, during or after conditioning therapy in patients who developed VOD. 5 There is also preliminary evidence that antithrombotic agents might be able to alter the natural history of VOD. 6, 7 Due to these results, we agree with Duggan and colleagues that it is reasonable to postulate a higher prevelance of inherited hypercoagulable abnormalities in BMT patients with VOD. In their study, the prevalence of the prothrombin gene variant in patients who developed VOD was much higher (13%) than would be expected. However, none of these patients had factor V Leiden mutation. Conversely, our preliminary results revealed a strong association between factor V Leiden mutation and VOD in pediatric allogeneic BMT patients. We recognize that the number of patients in both studies is small to draw a conclusion. However, with these results we believe that both factor V Leiden and prothrombin 20210 G-A mutations may increase the risk of VOD in BMT patients. It would be reasonable to test for these two genetic variants associated with venous thrombosis before BMT and early intervention or even prophylaxis for VOD may be considered for patients with these mutations.
M Ertem
Ankara Toxoplasmosis appears to be a rare opportunistic protozoal infection following hematopoietic stem cell transplantation (HSCT). The disease occurs almost exclusively from reactivation of latent microorganisms in seropositive recipients. In a recent review, only 55 cases had been reported after HSCT, 1 which contrasts with the high frequency of this complication in other patient populations with severe cellular immunodeficiencies, mainly advanced acquired immunodeficiency syndrome (AIDS). 2 Most cases have been reported in allogeneic HSCT recipients, with only anecdotal reports after autologous transplantation. 1 The seroprevalence for Toxoplasma gondii varies greatly between countries, ranging from less than 15% in some North American studies 3 and in pediatric wards, to 50-80% of adult HSCT recipients in countries with high endemicity such as France. 4 Probably one of the main reasons for the great variability in the frequency of diagnosed cases of toxoplasmosis after HSCT is this varying seroprevalence; the frequency has been estimated to average 0.8%, 5 with Ͻ0.4% in areas of low endemicity to 2-3% in those with high antibody prevalence. These differences may contribute to a wide range of policies regarding pretransplantation serology in donors and recipients, availability of diagnostic tests for toxoplasmosis and use of specific prophylaxis against this infection among different institutions in Europe. In early 1999 the EBMT-IDWP distributed among its members a survey in order to better clarify current frequencies and policies regarding toxoplasmosis after HSCT. Since our main interest was to study the most recently
